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Abstract 
N2-(4-Hydroxyphenyl)-2'-deoxyguanosine-5'-O-DMT-3'-phosphoramidite has been synthesized and 
used to incorporate the N2-(4-hydroxyphenyl)-2'-dG (N2-4-HOPh-dG) into DNA, using solid-state 
synthesis technology.  The key step to obtaining the xenonucleoside is a palladium (Xantphos-
chelated) catalyzed N2-arylation (Buchwald-Hartwig reaction) of a fully protected 2'-
deoxyguanosine derivative by 4-isobutyryloxybromobenzene. The reaction proceeded in good yield 
and the adduct was converted to the required 5'-O-DMT-3'-O-phosphoramidite by standard 
methods. The latter was used to synthesize oligodeoxynucleotides in which the N2-4-HOPh-dG 
adduct was incorporated site-specifically.  The oligomers were purified by reverse-phase HPLC. 
Enzymatic hydrolysis and HPLC analysis confirmed the presence of this adduct in the oligomers.  
 
 
 
 
Keywords    Benzene DNA adduct; Hydroquinone; p-Benzoquinone; Buchwald-Hartwig reaction;  
N2-(4-Hydroxyphenyl)-2'-deoxyguanosine 
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INTRODUCTION 
Humans are exposed to benzene from different sources such as automobile exhaust fumes, 
cigarette smoke and in industries involved in rubber manufacture, crude oil, gasoline, and 
chemical manufacturing.  Benzene has been linked to a number of chronic conditions of the 
haematopoietic system of exposed individuals, due to its metabolism in the liver and bone 
marrow, to more reactive species.[1] These chronic effects include leucopenia, thrombocytopenia, 
pancytopenia, anemia, and myelodysplastic syndrome. More importantly, benzene is a 
recognized human leukemogen.[2,3] Several epidemiologic studies have established a relationship 
between occupational exposure to benzene and human leukemia, especially acute myelogenous 
leukemia (AML).[4,5]   
Inhaled benzene is first metabolized in the liver, where it is converted by cytochrome P450-
2E1 to benzene oxide, then to phenol, hydroquinone (HQ) and other phenolic metabolites.[6,7] 
These compounds may travel to the bone marrow, the main target organ of benzene, where they 
are oxidized to genotoxic quinones such as p-benzoquinone (p-BQ) and o-BQ by the high levels 
of myeloperoxidase (MPO) in this tissue (Figure 1). The mutagenic potential of benzene and its 
major metabolites such as HQ and p-BQ has been extensively investigated.[8] Studies using 
mammalian systems have shown that benzene metabolites induce base substitution and deletion 
in various cell lines, animal tissues, and blood from exposed individuals.[8] 
The precise mechanisms underlying the benzene-induced mutagenesis remain poorly 
understood. There are numerous reports dealing with the detection of covalent DNA adducts by 
HQ and p-BQ in vitro.[8,9] These two compounds are stable metabolites derived from benzene, 
and p-BQ is also present in a number of drugs and chemical substances.[10-12] Both metabolites 
form exocyclic benzetheno adducts with dG, dA and dC.[13-17] Although they were not detected 
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in tissues such as the bone marrow by 32P-postlabeling,[18,19] their in vivo formation by similar 
mechanisms to those seen in in vitro reactions is expected, given that the yields of these adducts 
were high in the latter. Using site-directed mutagenesis, we recently showed that all three p-BQ 
adducts are highly mutagenic in S. cerevisiae by predominantly causing deletion mutations.[20] 
We have also shown that these p-BQ adducts, when present in DNA, are substrates for human 
apurinic/apyrimidinic (AP) endonuclease (APE1), which directly incises the phosphodiester 
bond 5' to the adduct.[21-24] 
Although benzene-derived DNA adducts have been identified in vitro, the in vivo detection 
of such adducts has been a subject of controversy.  Using 32P-postlabeling, Bauer et al showed 
the formation of several DNA adducts in the livers of rabbits treated with benzene.[25] Later, 
the Bodell group discovered in vivo adducts in a human promyelocytic (HL-60) cell line[18,26] 
and bone marrow of mice[19] that were treated with benzene, HQ, or p-BQ. They found that the 
DNA adducts formed after benzene administration in mouse bone marrow are identical to 
those produced in HL-60 or mouse bone marrow cells treated with HQ or p-BQ. Moreover, the 
observed induction of toxicity in the bone marrow was paralleled by formation of DNA 
adducts.[19] By 32P-postlabeling, the principal adduct found in the cells targeted by benzene has 
the same chromatographic properties as N2-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-
phosphate.[18,26] This adduct can also be formed in vitro by allowing guanosine 3'-phosphate to 
react with p-BQ.[18,26] To date, the biochemical properties and biological importance of this 
adduct await investigation.  
In order to understand the molecular mechanism by which HQ and p-BQ exert their 
mutagenic effects, it is important to study their principal adduct formed in vivo, N2-(4-
hydroxyphenyl)-2'-deoxyguanosine (N2-4-HOPh-dG), regarding its potential effects on DNA 
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replication and repair. Such studies would be greatly facilitated with oligonucleotides 
containing a site-specific adduct. Previously, we have synthesized the phosphoramidites of 
exocyclic p-BQ-dA, p-BQ-dC and one of the p-BQ-dG adducts and incorporated them site-
specifically into oligomeric DNA.[27,28] In this work, we report for the first time the synthesis 
of N2-4-HOPh-dG-phosphoramidite and its incorporation into defined DNA oligonucleotides.  
 
RESULTS AND DISCUSSION 
Previously, Pongracz and Bodell[26] reported the synthesis of N2-(4-hydroxyphenyl)-2'-
deoxyguanosine-3'-phosphate as the 3'-phosphate. We have now successfully synthesized the 
fully-protected N2-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosohoramidite 7, by a completely 
new method (Scheme 1) which gave better yields. Our approach is similar to that used previously 
for the synthesis and incorporation of the 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP) adducts into DNA in which the key procedure is a Buchwald-Hartwig (BH) reaction.[29,30] 
Compound 1 when coupled with 4-isobutyryloxybromobenzene 2 under the conditions of the 
Buchwald-Hartwig reaction gave compound 3 in 80% yield. Removal of the 6-O-benzyl group 
from the purine moiety was then accomplished by hydrogenolysis over a palladium catalyst to 
give compound 4, which, after purification by column chromatography, was obtained in 88% 
yield. The silyl protecting groups of compound 4 were removed by HF in pyridine, to give 
compound 5 in 76% yield after purification. The electrospray mass spectrum of this compound 
showed an intense protonated molecular ion at m/z 430 (M+H)+ and the natriated species at m/z 
at 452 (M+Na)+ (Figure 2). Reaction of compound 5 with DMT-Cl in pyridine produced 
compound 6 in 90% yield, which was then allowed to react with 2-cyanoethyl N, N, N, N-
tetraisopropyl phosphane to produce the fully protected phosphoramidite compound 7. All of the 
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above compounds were identified by MS, 1H NMR, 13C NMR and in the case of compound 7, 31P 
NMR analysis was used as well (See 1H NMR of 7 in Figure 3). The latter was then used to 
introduce the xenonucleoside into defined oligonucleotides by DNA synthesizer. The 
composition of the oligomers was confirmed after enzymatic digestion of the DNA oligomers to 
nucleosides, followed by HPLC analysis, which showed that the N2-4-HOPh-dG residual 
survived the conditions used in the DNA synthesis and the deprotection procedure (Figure 4). 
The biochemical work is underway to evaluate the mutagenic potential of this adduct as well as 
possible repair mechanism(s) that acts on it using these oligonucleotides. 
 
EXPERIMENTAL  
Caution: The organic solvents used in this work should be stored and used in a well-
ventilated hood. 
Chemicals and Reagents.  
All reagents and solvents employed were of commercial grade and were used as such, unless 
otherwise specified.  NMR (1H and 13C) spectra were recorded on a Gemini 300 spectrometer.  
Samples prepared for NMR analysis were dissolved in CDCl3 or DMSO-d6.  Chemical shifts are 
reported in ppm relative to TMS in the proton spectra and to the deuterated solvent in the carbon 
spectra.  Mass spectra were recorded on a Micromass Trio in fast atom bombardment (FAB) 
mode.  Thin-layer chromatography (TLC) was performed on silica gel sheets (riedel-deHaën, 
Sleeze, Germany) containing a fluorescent indicator.  Components were visualized by UV light 
(λ = 254 nm) or by spraying with a solution of phosphomolybdic acid.  Flash column 
chromatography separations were carried out on 60 Å (230-400 mesh) silica gel (Silica-P Flash 
Silica Gel obtained from Silicycle, Quebec, QC, Canada).  All experiments dealing with 
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moisture or air-sensitive compounds were conducted under dry nitrogen.  The starting materials 
and reagents, unless otherwise specified, were the best commercial grades available (Aldrich, 
Fluka) and were used without further purification. After purification all new products showed a 
single spot on TLC analysis.  
HPLC. Solvent systems included acetonitrile (solvent A), triethylammonium acetate (0.1 M, 
pH 7.0, solvent B), and potassium phosphate buffer (0.01 M, pH 4.5, solvent C). System 1: 
Oligonucleotides were purified using a PRP-1-C18 column (305 X 7 mm, 10 µm, Hamilton 
Corp.). The initial concentration of solvent A was 10% and solvent B was 90%, then solvent A 
was increased linearly to 38% over 40 min at a flow rate of 3 ml/min. System 2:  This was used 
for the analysis of the enzyme digest of the oligonucleotides and was performed with a 
Supelcosil LC-18-DB column (25 x 0.46 cm, 5 µm, Supelco Inc.) using 0% solvent A, 100% 
solvent C at start. Solvent A was linearly increased to 12% over 30 min, then to 40% over 15 
min where it was held for 10 min at a flow rate of 1 ml/min.  The HPLC instrument was an 
Agilent 1100 series. 
Ultraviolet spectra were recorded on an Agilent 8453 spectrophotometer using 0.2 cm 
cuvette. TLC was performed on silica gel 60, F254 plates. Column chromatography was 
performed using silica gel 60 with elution under pressure. 
Chemical Syntheses (Scheme 1).  
N2-(4-Isobutyryloxyphenyl)-O6-benzyl-3',5'-bis-O-(tert-butyldimethylsilyl)-2'-deoxyguanosine 
(3). An oven-dried 100 mL two-necked round-bottomed flask was charged with the protected 
purine nucleoside 1[31] (1.17 g. 2 mmol), cesium carbonate (0.92 g, 2.8 mmol), Pd2(dba)3 (230 
mg, 0.25 mmol), xantphos (480 mg, 0.8 mmol), 4-isobutyryloxybromobenzene (2, 0.724 g, 2.98 
mmol) and toluene (15 mL) under a nitrogen atmosphere.  This mixture was stirred for 30 min at 
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room temperature, later heated at 80oC for 6 h.  It was cooled to room temperature, the solids 
were filtered, and the solid cake was washed with ethyl acetate.  The filtrate was evaporated to 
dryness and the residue was purified by silica gel column chromatography using CH2Cl2:ethyl 
acetate (98:2) as the eluant to give pure 3 (1.2 g, 80%). 1H NMR (CDCl3): δ 8.09 (s, 1H), 7.67 
(d, 2H), 7.55 (m, 2H),7.45-7.33 (m, 3H), 7.28 (br s, 1H), 7.09 (d, 2H), 6.46 (t, 1H), 5.68 (s, 2H), 
4.64 (m, 1H), 4.08 (m, 1H),  3.88-3.85 (m, 2H), 2.87 (m, 1H), 2.72-2.39 (m, 2H), 1.40 (s, 3H), 
1.38 (s, 3H), 0.98 (s, 9H), 0.97 (s, 9H), 0.16 (s, 6H), 0.15 (s, 6H). 13C NMR (CDCl3): δ  175.43, 
160.15, 155.26, 152.81, 145.11, 137.79, 137.35, 136.08, 128.03, 127.68, 127.60, 121.24, 119.37, 
116.09, 87.35, 83.61, 77.42, 77.00, 76.57, 71.64, 67.79, 62.53, 41.01, 33.80, 25.68, 25.47, 18.67, 
18.09, 17.67, -4.94, -5.06, -5.66, -5.77. ESI (M+H) 748.  
N2-(4-Isobutyryloxyphenyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-2'-deoxyguanosine (4).  To a 
solution of 3 (1.2 g, 1.6 mmol) in ethyl acetate (50 mL) was added a 10% palladium-on-carbon 
(150 mg) catalyst.  The flask was evacuated (50 Torr) and flushed with hydrogen three times.  
The mixture was shaken under hydrogen for 16 h at 50 psi, filtered through a pad of Celite to 
remove the catalyst, and then concentrated under reduced pressure.  The residue was purified by 
column chromatography using 3% methanol in methylene chloride to obtain the pure 
debenzylated product 4 as a glassy solid (0.930 gm 88%). 1H NMR (CDCl3): δ 11.76 (br s, 1H), 
9.75 (br s, 1H),  8. 14 (d, 2H), 8.09 (s, 1H), 7.10 (d, 2H), 6.41 (t, 1H), 4.63 (m, 1H), 4.07 (m, 
2H), 2.87 (m, 1H), 2.52 (m, 2H), 1.40 (s, 3H), 1.38 (s, 3H), 1.00 (s, 9H), 0.98 (s, 9H), 0.18 (s, 
6H), 0.16 (s, 1H). 13C NMR (CDCl3): δ  175.54, 158.83, 150.62, 149.57, 146.05, 136.46, 136.31, 
121.33, 121.02, 118.16, 87.64, 84.04, 71.76, 62.75, 41.71, 34.09, 25.92, 25.71, 18.94, 18.35, 
17.90, -4.68, -4.82, -5.41, -5.53. ESI (M+H) 658.  
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Preparation of N2-(4-isobutyryloxyphenyl)-2'-deoxyguanosine (5).  To an ice-cold solution of 
4 (0.9 g, 1.37 mmol) in pyridine (20 mL) was added HF/Py (2.2 mL, 70% of HF in Py from 
Aldrich Chemical Co.) over a period of 3 min.  The mixture was stirred at room temperature 
overnight, then poured into ice-cold water (100 mL) containing NaHCO3 (6.5 g) and stirred for 2 
h.  The reaction mixture was evaporated to dryness and co-evaporated with methanol three times 
and the residual material was adsorbed onto silica gel using methanol as a solvent. It was 
purified by silica gel using 15% methanol in methylene chloride to obtain the pure 5 as a white 
solid (450 mg, 76%).  1H NMR (DMSO-d6): δ 10.67 (br s, 1H), 9.01 (s, 1H), 8.03 (s, 1H), 7.61 
(d, 2H), 7.09 (d, 2H), 6.195 (t, 1H), 5.27 (br s, 1H), 4.89 (br s, 1H),  3.81 (m, 1H), 3.50 (m, 2H), 
2.78 (m, 1H), 2.59 (m, 1H), 2.28 (m, 1H), 1.22 (s, 3H), 1.20 (s, 3H). 13C NMR (DMSO-d6): δ  
175.96, 157.14, 150.09, 149.97, 146.32, 137.18, 122.73, 120.95, 118.97, 88.35, 83.64, 71.31, 
62.29, 33.97, 19.38. ESI (M+H) 429.  
N2-(4-Isobutyryloxyphenyl)-5′-O-(4.4′-dimethoxytrityl)-2′-deoxyguanosine (6):  To a solution 
of 5 (0.428 g, 1 mmol) in pyridine (15 mL) was added DMT chloride (0.440 g, 1.3 mmol) as a 
solid and the mixture was stirred at room temperature for 3 h.  TLC (CH2Cl2: MeOH: 85:15) of 
the mixture showed the reaction to be ~90% complete.  The reaction was quenched by adding 
methanol (5 mL) and the mixture was stirred for 30 min at room temperature, and then 
concentrated under reduced pressure.  To the residue was added aqueous NaHCO3 (25 mL) and 
the mixture was extracted with methylene chloride. The methylene chloride extract was dried 
over anhydrous MgSO4, filtered and concentrated. The crude product was purified by column 
chromatography using TEA-treated silica gel and CH2Cl2: MeOH (95:5) as the eluant to give 
pure 6 (550 mg, 90% yield based on consumed starting material). The column was further eluted 
with 15% methanol in methylene chloride to recover the unreacted starting material (70 mg). 1H 
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NMR (CDCl3): δ 10.01 (br s, 1H), 7.75 (s, 1H), 7.58 (d, 2H), 7.41-7.16 (m, 10H), 6.89 (d, 2H), 
6.79 (d, 4H), 6.15 (t, 1H), 4.46 (m, 1H),  4.05 (m, 1H), 3.73 (s, 6H), 3.27 (m, 2H), 2.84 (m, 1H), 
2.72 (m, 1H), 2.41 (m, 1H). 13C NMR (CDCl3): δ  176.51, 158.38, 150.19, 149.95, 146.30, 
144.68, 136.73, 135.90, 135.86, 129.95, 128.13, 127.69, 126.71, 123.31, 121.49, 118.59, 113.00, 
86.23, 85.61, 83.98, 71.44, 64.25, 55.09, 39.52, 34.07, 18.83.  ESI (M+H) 732.  
N2-(4-Isobutyryloxyphenyl)-5′-O-(4,4’-dimethoxytrityl)-3′-O-[N,N-diisopropylamino-(2-
cyanoethoxy)-phosphinyl]-2′-deoxyguanosine (7). Compound 6 (256 mg, 0.35 mmol) was co-
evaporated with dry toluene (3 x 10 mL), and the residue was redissolved in dry methylene 
chloride (10 mL). Tetrazole (28 mg, 0.40 mmole) was then added followed by 2-cyanoethyl 
N,N,N,N-tetraisopropylphosphane (147 mg, 0.49 mmole). The reaction mixture was stirred at 
room temperature for 2 h under nitrogen and then poured into aqueous NaHCO3 (10%, 10 mL). 
The methylene chloride layer was separated and the aqueous layer was extracted once with 
methylene chloride (20 mL).  The combined methylene chloride extract was dried over Na2SO4, 
filtered and concentrated under reduced pressure to obtain the desired crude product 7 as an oil.  
The crude residue was purified on a silica gel column pre-treated with triethylamine, using 
methylene chloride:acetone (3:2) as the eluant. The fractions containing the pure material were 
collected and concentrated under reduced pressure and the resulting solid was triturated with 
isorpropyl ether and filtered to give pure 7 as a white solid (240 mg, 73%). 1H NMR (CDCl3): δ 
8.76 (br s, 1H), 8. 02 (br s, 1H), 8.01 (d, 1H), 7.88 (d, 1H), 7.48-7.25 (m, 10H), 7.02 (d, 2H), 
6.85 (m. 4H), 6.41 (t, 1H), 4.71 (m, 1H), 4.34 (m, 1H), 3.80 (s, 6H), 3.65 – 3.74 (m, 5H), 3.41 
(m, 2H), 3.09 (m, 1H), 2.87 – 2.47 (m, 3H), 1.38-1.16 (m, 18H). 13C NMR (CDCl3): δ  175.62, 
158.94, 158.55, 150.92, 149.72, 146.26, 144.52, 136.22, 135.63, 135.53, 130.13, 130.07, 130.02, 
128.16, 128.10, 127.85, 126.90, 121.54, 121.26, 118.46, 117.61, 113.16, 86.48, 85.81, 84.15, 
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74.01, 63.66, 58.40, 58.21, 55.17, 46.13, 43.39, 43.34, 43.27, 43.21, 40.24, 34.12, 24.58, 24.55, 
24.51, 20.35, 20.27, 20.18, 18.96. 31P NMR (CDCl3): δ 150.09, 149.60. 
Solid-phase synthesis of DNA oligonucleotides. The fully-protected phosphoramidite 
compound 7 was used to synthesize three different oligonucleotides at the 1 µmole scale: a 22-
mer, a 25-mer and a 40-mer using an Applied Biosystem 394 automated DNA synthesizer by 
standard phosphoramidite chemistry. Phenoxyacetyl (PAC) was used as the N-ptotecting group 
in the synthesis of the DNA oligomers. Because amidite 7 has very limited solubility in 
acetonitrile, dry methylene chloride (100%) was used to dissolve the amidite 7, which was used 
in the DNA synthesis. The coupling time for the amidite 7 was increased to 15 min, and the 
coupling efficiency at the N2-4-HOPh-dG step was 97% for all oligonucleotides. The 
oligonucleotides were then cleaved from the resin and deprotected by means of 28% ammonium 
hydroxide containing 1% of 2-mercaptoethanol for 2 hours at 65°C. The latter reagent prevents 
oxidative degradation of the N2-4-HOPh-dG lesion. The oligonucleotides were purified by 
reverse phase HPLC on a C-18 column. The sequences of the DNA oligomers synthesized are as 
follows: 
1: 5'-GTAAGCTXGATCCTCTAGAGCG-3' (22-mer) 
2: 5'-CCGCTAXCGGGTACCGAGCTCGAAT-3' (25-mer) 
3: 5'-TTGCTTTGTCACCCAGGCTXGACTGCAGTGGTACAATCAT-3' (40-mer) 
X= N2-4-HOPh-dG 
Enzymatic digestion of the oligomers. The composition of the oligomers was confirmed by 
enzymatic digestion of the DNA oligomers to nucleotides, which were identified by HPLC 
analysis. A defined oligonucleotide (1.0 A260 unit) was dissolved in 44  µL of deionized water, 
0.8 µL of 1M MgCl2, and 3.5 µL of 0.5M Tris-HCl buffer (pH 7.5) and digested with snake 
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venom phosphodiesterase (2.5 µL) and bacterial alkaline phosphatase (4.0 µL) at 37 ºC for 16 h. 
The digested mixture was then analyzed on a C-18 reverse-phase HPLC Supelcosil column using 
solvent system 2 noted above.  
 
 
 
 13 
Acknowledgments 
This work was supported by NIH grant CA72079 (to B.H.) and was administrated by the 
Lawrence Berkeley National Laboratory under Department of Energy contract DE-AC03-
76SF00098. 
 14 
REFERENCES 
1. NTP Toxicology and Carcinogenesis Studies of Benzene (CAS No. 71-43-2) in F344/N Rats 
and B6C3F1 Mice (Gavage Studies). Natl. Toxicol. Program Tech. Rep. Ser. 1986, 289, 1-
277. 
2. IARC, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. 
Some industrial chemicals and dyestuffs. International Agency for Research on Cancer: 
Lyon, France, 1982, Vol. 29. 
3. NTP, 11th Report on carcinogens. U.S. Department of Health and Human Services, National 
Toxicology Program, Atlanta, GA, 2005. 
4. Yin, S.-N.; Hayes, R.; Linet, M.; Li, G.; Dosemeci, M.; Travis, L.; Zhang, Z.; Li, D.; Chow, 
W.; Wacholder, S.; Blot, W. Recent studies of human exposure to benzene in China and 
Europe  An expanded cohort study of cancer among benzene-exposed workers in China. 
Environ. Health Perspect. 1996, 1339-1341. 
5. Glass, D. C.; Gray, C. N.; Jolley, D. J.; Gibbons, C.; Sim, M. R.; Fritschi, L.; Adams, G. G.; 
Bisby, J. A.; Manuell, R. Leukemia risk associated with low-level benzene exposure. 
Epidemiology 2003, 14, 569-577. 
6. Snyder, R.; Hedli, C. C. An overview of benzene metabolism. Environ. Health Perspect. 
1996, 104 Suppl 6, 1165-1171. 
7. Lovern, M. R.; Cole, C. E.; Schlosser, P. M. A review of quantitative studies of benzene 
metabolism. Crit. Rev. Toxicol. 2001, 31, 285-311. 
8. Whysner, J.; Reddy, M. V.; Ross, P. M.; Mohan, M.; Lax, E. A. Genotoxicity of benzene and 
its metabolites. Mutat. Res. 2004, 566, 99-130. 
 15 
9. Exocyclic DNA Adducts in Mutagenesis and Carcinogenesis. Proceedings of the 2nd 
international conference. Heidelberg, Germany, September 1998. IARC Sci Publ 1999, 150, 
1-361. 
10. Zheng, J.; Hanzlik, R. P. Dihydroxylated mercapturic acid metabolites of bromobenzene. 
Chem. Res. Toxicol. 1992, 5, 561-567. 
11. Pascoe, G. A.; Calleman, C. J.; Baille, T. A. Identification of S-(2,5-dihydroxyphenyl)-
cysteine and S-(2,5-dihydroxyphenyl)-N-acetyl-cysteine as urinary metabolites of 
acetaminophen in the mouse. Evidence for p-benzoquinone as a reactive intermediate in 
acetaminophen metabolism. Chem. Biol. Interact. 1988, 68, 85-98. 
12. McDonald, T. A.; Waidyanatha, S.; Rappaport, S. M. Measurement of adducts of 
benzoquinone with hemoglobin and albumin. Carcinogenesis 1993, 14, 1927-1932. 
13. Jowa, L.; Winkle, S.; Kalf, G.; Witz, G.; Snyder, R. Deoxyguanosine adducts formed from 
benzoquinone and hydroquinone. Adv. Exp. Med. Biol. 1986, 197, 825-832. 
14. Jowa, L.; Witz, G.; Snyder, R.; Winkle, S.; Kalf, G. F. Synthesis and characterization of 
deoxyguanosine-benzoquinone adducts. J. Appl. Toxicol. 1990, 10, 47-54. 
15. Pongracz, K.; Bodell, W. J. Detection of 3'-hydroxy-1,N6-benzetheno-2'-deoxyadenosine 3'-
phosphate by 32P postlabeling of DNA reacted with p-benzoquinone. Chem. Res. Toxicol. 
1991, 4, 199-202. 
16. Pongracz, K.; Kaur, S.; Burlingame, A. L.; Bodell, W. J. Detection of (3'-hydroxy)-3,N4-
benzetheno-2'-deoxycytidine-3'-phosphate by 32P-postlabeling of DNA reacted with p-
benzoquinone. Carcinogenesis 1990, 11, 1469-1472. 
17. Gaskell, M.; Jukes, R.; Jones, D. J.; Martin, E. A.; Farmer, P. B. Identification and 
characterization of (3",4"-dihydroxy)-1,N2-benzetheno-2'-deoxyguanosine 3'-
 16 
monophosphate, a novel DNA adduct formed by benzene metabolites. Chem. Res. Toxicol. 
2002, 15, 1088-1095. 
18. Levay, G.; Pongracz, K.; Bodell, W. J. Detection of DNA adducts in HL-60 cells treated with 
hydroquinone and p-benzoquinone by 32P-postlabeling. Carcinogenesis 1991, 12, 1181-1186. 
19. Bodell, W. J.; Pathak, D. N.; Levay, G.; Ye, Q.; Pongracz, K. Investigation of the DNA 
adducts formed in B6C3F1 mice treated with benzene: implications for molecular dosimetry. 
Environ. Health Perspect. 1996, 104 Suppl 6, 1189-1193. 
20. Xie, Z.; Zhang, Y.; Guliaev, A. B.; Shen, H.; Hang, B.; Singer, B.; Wang, Z. The p-
benzoquinone DNA adducts derived from benzene are highly mutagenic. DNA Repair (Amst) 
2005, 4, 1399-1409. 
21. Chenna, A.; Hang, B.; Rydberg, B.; Kim, E.; Pongracz, K.; Bodell, W. J.; Singer, B. The 
benzene metabolite p-benzoquinone forms adducts with DNA bases that are excised by a 
repair activity from human cells that differs from an ethenoadenine glycosylase. Proc. Natl. 
Acad. Sci. USA 1995, 92, 5890-5894. 
22. Hang, B.; Chenna, A.; Fraenkel-Conrat, H.; Singer, B. An unusual mechanism for the major 
human apurinic/apyrimidinic (AP) endonuclease involving 5' cleavage of DNA containing a 
benzene-derived exocyclic adduct in the absence of an AP site. Proc. Natl. Acad. Sci. USA 
1996, 93, 13737-13741. 
23. Hang, B.; Chenna, A.; Sagi, J.; Singer, B. Differential cleavage of oligonucleotides 
containing the benzene-derived adduct, 1,N6-benzetheno-dA, by the major human AP 
endonuclease HAP1 and Escherichia coli exonuclease III and endonuclease IV. 
Carcinogenesis 1998, 19, 1339-1343. 
 17 
24. Guliaev, A. B.; Hang, B.; Singer, B. Structural insights by molecular dynamics simulations 
into specificity of the major human AP endonuclease toward the benzene-derived DNA 
adduct, pBQ-C. Nucleic. Acids. Res. 2004, 32, 2844-2852. 
25. Bauer, H.; Dimitriadis, E. A.; Snyder, R. An in vivo study of benzene metabolite DNA 
adduct formation in liver of male New Zealand rabbits. Arch. Toxicol. 1989, 63, 209-213. 
26. Pongracz, K.; Bodell, W. J. Synthesis of N2-(4-hydroxyphenyl)-2'-deoxyguanosine 3'-
phosphate: comparison by 32P-postlabeling with the DNA adduct formed in HL-60 cells 
treated with hydroquinone. Chem. Res. Toxicol. 1996, 9, 593-598. 
27. Chenna, A.; Singer, B. Large scale synthesis of p-benzoquinone-2'-deoxycytidine and p-
benzoquinone-2'-deoxyadenosine adducts and their site-specific incorporation into DNA 
oligonucleotides. Chem. Res. Toxicol. 1995, 8, 865-874. 
28. Chenna, A.; Singer, B. Synthesis of a benzene metabolite adduct, 3"-hydroxy-1,N2-
benzetheno-2'-deoxyguanosine, and its site-specific incorporation into DNA 
oligonucleotides. Chem. Res. Toxicol. 1997, 10, 165-171. 
29. Lakshman, M. K. Synthesis of biologically important nucleoside analogs by Palladium-
catalyzed C-N bond-formation. Curr. Org. Synth. 2005, 2, 83-112. 
30. Bonala, R.; Torres, M. C.; Iden, C. R.; Johnson, F. Synthesis of the PhIP adduct of 2'-
deoxyguanosine and its incorporation into oligomeric DNA. Chem. Res. Toxicol. 2006, 19, 
734-738. 
31. Harwood, E. A.; Sigurdsson, S. T.; Edfeldt, N. B. F.; Reid, B. R.; Hopkins, P. B. Synthesis 
and preliminary structural characterization of nitrous acid interstrand cross-linked duplex 
DNA. J. Am. Chem. Soc. 1999, 121, 5081-5082. 
 
 18 
Figure legends 
Figure 1: The metabolic route from benzene to the formation of HQ and p-BQ. These two 
stable metabolites may react with guanine in the bone marrow to form N2- (4-hydroxyphenyl)-2'-
deoxyguanosine (N2-4-HOPh-dG). 
 
Figure 2: Electrospray mass spectrum of N2-4-HOPh-dG (5). 
 
Figure 3: 1H NMR of N2-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosohoramidite (7).  
 
Figure 4: (A) HPLC profile of 2'-deoxynucleosides obtained as a result of enzymatic digestion 
of the N2-4-HOPh-dG-containing 40-mer. (B) HPLC profile of N2-4-HOPh-dG. 
 
Schemes 
Scheme 1:  The synthesis of the fully protected N2- (4-hydroxyphenyl)-2'-deoxyguanosine-
3’-phosphoramidite 7. 
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